Given the critical role of TP53 in cancer, numerous therapeutic strategies are being explored to target TP53 mutations. These include small molecules that reactivate mutant p53, gene therapy approaches to restore normal TP53 function, and immunotherapies that enhance the immune system's ability to target cells with dysfunctional p53. However, the clinical application of these therapies is still under active investigation.
